DelveInsight’s Dyslipidemia Market Insights report proffers a detailed comprehension of Dyslipidemia market size by treatment, epidemiology, emerging therapies, Dyslipidemia market share of the individual therapies, current and forecasted Dyslipidemia market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Some of the salient features from the Dyslipidemia Market Report:
For further information on Market Impact by Therapies, Download Dyslipidemia Market sample @ Dyslipidemia Market Scenario
Dyslipidemia Overview
Dyslipidemia is a condition caused by the abnormal fluctuation in the levels of cholesterol as well as lipoproteins such as High-Density Lipoprotein (HDL) and Low-Level Lipoprotein (LDL). Besides tagging them as an important component of the living cells, their existence in escalated levels can increase the risk of getting a heart attack or any other major health issue. Dyslipidemia is segmented into two major types on the basis of their causes known as Primary Dyslipidemia and Secondary Dyslipidemia
Dyslipidemia Epidemiology Segmentation
Kindly provide some epidemiology details.
The Dyslipidemia Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Dyslipidemia Pipeline Therapies and Key Companies
To know about more pipeline therapies under different development phases visit @ Dyslipidemia Pipeline Assessment, Patient Pool, and Emerging Therapies
Dyslipidemia Market Landscape
Dyslipidemia prevention, as well as Dyslipidemia treatment, should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, ezetimibe, fibrates (fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil), and nicotinic acid (niacin, also called vitamin B3, PP) represent the second-choice drugs. In addition, anti-PCSK9 drugs (evolocumab, alirocumab, and inclisiran) provide an effective solution for patients with familial hypercholesterolemia (FH) and statin intolerance at very high cardiovascular risk. Another class of drugs includes bile acid-binding resins (including cholestyramine, colesevelam, and colestipol) are orally administered anion-exchange resins that are neither absorbed systemically nor metabolized by digestive enzymes.
A robust pipeline in the Dyslipidemia treatment landscape is indicative of the very high market potential of Dyslipidemia drugs, this includes pipeline drugs like Pemafibrate (K-877) is being developed by the Kowa Company is a selective Peroxisome Proliferator-Activated Receptors (PPARs) modulator. Pemafibrate is currently undergoing Phase III (NCT04716595) trial to assess its ability to improve patients’ health. AstraZeneca in collaboration with Parexel is developing AZD8233 which is currently in Phase II of clinical trials. Another major anticipated Dyslipidemia drug in the pipeline is ARO-ANG3, it is an investigational agent from Arrowhead Pharmaceuticals, it belongs to the class of Antihyperlipidemic which is in Phase II (NCT04832971) developmental stage. Also, Eli Lilly and Company’s investigational candidate for Dyslipidemia is LY3475766 which is currently in Phase I stage of clinical trials.
A robust pipeline of novel and emerging therapies, increasing global geriatric population, increase in the prevalence of lifestyle-related (obesity) and cardiovascular disorders serve as major aspects for Dyslipidemia market growth in the upcoming years. The increase in the Dyslipidemia market is a direct outcome related to the increasing Dyslipidemia prevalent population and the anticipated launch of emerging Dyslipidemia drugs in the coming years.
On the contrary, the unreported and undiagnosed Dyslipidemia cases, a significant proportion of treated patients do not reach the recommended treatment goal and an increase in the availability of generic drugs can be considered some of the potential drawbacks of the Dyslipidemia market.
Know which therapy is expected to score the touchdown first @ Dyslipidemia Market Landscape and Forecast
Scope of the Dyslipidemia Report
Table of Contents
1
Key Insights
2
Executive Summary of Dyslipidemia
3
SWOT Analysis of Dyslipidemia
4
Dyslipidemia: Market Share (%) Distribution Overview at a Glance: By Country
5
Dyslipidemia Epidemiology and Market Methodology
6
Dyslipidemia: Disease Background and Overview
7
Dyslipidemia Epidemiology and Patient Population
8
Dyslipidemia Epidemiology Scenario: 7MM
9
The United States Epidemiology in Dyslipidemia
10
EU-5 Epidemiology in Dyslipidemia
11
Japan Epidemiology in Dyslipidemia
12
Current Treatment Practices of Dyslipidemia
13
Unmet Needs in Dyslipidemia
14
Patient Journey of Dyslipidemia
15
Key Endpoints in Dyslipidemia Clinical Trials
16
Marketed Therapies in Dyslipidemia
17
Emerging Therapies in Dyslipidemia pipeline
17.1
Pemafibrate (K-877): Kowa Company
17.2
LY3475766: Eli Lilly and Company
18
Conjoint Analysis of Dyslipidemia
19
Dyslipidemia: Seven Major Market Analysis
20
7MM Market Size
21
United States Market Size
22
EU-5 Market Size
23
Japan Market Size
24
Dyslipidemia Market Access and Reimbursement of Dyslipidemia Therapies
25
Dyslipidemia Market Drivers
26
Dyslipidemia Market Barriers
27
Appendix
28
DelveInsight Capabilities
29
Disclaimer
30
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Kunjika AgarwalEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/dyslipidemia-market